What is 3billion?
Based in Seoul, South Korea, 3billion is a pioneering gene sequencing company specializing in rare disease screening technology. The company leverages advanced genetic analysis to identify and diagnose rare genetic disorders, aiming to provide critical insights for both patients and healthcare providers. Its focus on a niche yet vital area of medical technology positions it as a key player in the burgeoning field of personalized medicine and genetic diagnostics. The company's commitment to innovation in this space is reflected in its continuous pursuit of funding to advance its research and development capabilities.
How much funding has 3billion raised?
3billion has raised a total of $291M across 3 funding rounds:
Series A
$268M
Series B
$10M
Series C
$13M
Series A (2018): $268M with participation from Korea Development Bank, The Wells Investment, and JW Assets
Series B (2019): $10M led by Korea Development Bank, The Wells Investment, and JW Assets
Series C (2021): $13M supported by Magna Investment, KOREA INVESTMENT & SECURITIES, The Wells Investment, Yuanta Investment, JW Assets, Kakao Investment, and Aventures Investment
Key Investors in 3billion
Korea Development Bank
Korea Development Bank is a state-owned policy development bank in South Korea, established in 1954 to finance and manage major industrial projects. It plays a crucial role in fostering the growth and competitiveness of strategic industries by meeting their evolving financial needs and facilitating corporate restructuring.
The Wells Investment
The Wells Investment is a venture capital and private equity firm focused on partnering with growth-stage companies in sectors like bio-healthcare and deep tech. They provide capital, management expertise, and networks to foster sustainable prosperity and drive industry change.
JW Assets
JW Assets, led by Will Rogers, Jr., offers expertise in marketing consulting, real estate, and business management strategy. The firm focuses on providing excellent professional service and ethical practices to corporations and small businesses, aiming to help clients achieve their goals efficiently.
What's next for 3billion?
With the recent major strategic investment, 3billion is poised for accelerated growth and expansion. The capital infusion is expected to fuel further research and development into novel gene sequencing techniques and rare disease screening methodologies. This strategic financing will likely enable the company to enhance its technological infrastructure, broaden its service offerings, and potentially expand its global footprint. The company's progression through multiple funding rounds, from Series A to Series C, suggests a robust business model and a clear vision for future success in the competitive biotechnology landscape.
See full 3billion company page
